Indies Pharma gets FDA approval on new drug - Jamaica Observer
Indies Pharma Jamaica is the first Jamaican company to have an ANDA approved by the FDA, unlocking a $400 million market for its generic drug Regadenoson, used for heart disease diagnostics. The company plans to divest its anti-cancer drug due to market shrinkage and aims to secure a distributor for its new drug in the U.S.
Reference News
Indies Pharma Jamaica is the first Jamaican company to have an ANDA approved by the FDA, unlocking a $400 million market for its generic drug Regadenoson, used for heart disease diagnostics. The company plans to divest its anti-cancer drug due to market shrinkage and aims to secure a distributor for its new drug in the U.S.
Indies Pharma Jamaica Limited aims to double revenues next year after FDA approval of its generic Regadenoson Injection, used for heart disease treatment. The company expects to hit $2 billion, possibly $3 billion by FY2025, with initial sales focused on the U.S. market.